LATOVETCEL
UNII 74A8KT7B4S

Substance Identification & Data

This profile provides standardized clinical and technical data for Latovetcel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 74A8KT7B4S.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
74A8KT7B4S
CAS Registry Number
N/A
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
LATOVETCEL
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C203132
National Cancer Institute reference terminology for clinical and research data.
INN ID
12666
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
structurallyDiverse
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
ITIS TSN
180691
Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.
NCBI Taxonomy
9796
Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Latovetcel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LATOVETCEL

Common Names & Synonyms

EQUINE ALLOGENEIC MESENCHYMAL STEM/STROMAL CELLS (MSCS) ISOLATED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) COLLECTED FROM DONOR HORSES. THE MSCS ARE SELECTED FOR BY GROWING THE PBMCS IN MEDIA CONTAINING FETAL BOVINE SERUM (FBS) AND DEXAMETHASONE AND THEN FURTHER EXPANDED IN MEDIA CONTAINING FBS (THE FINAL CELLS ARE CHARACTERIZED BY THEIR SPINDLE SHAPED MORPHOLOGY, AND BY EXPRESSION OF THE CELLULAR SURFACE MARKERS CD90 (>=95%) AND CD44 (>=85%) AND ABSENCE OF MHC CLASS II EXPRESSION (<=2%). THE CELLS SECRETE PROSTAGLANDIN E2 (PGE2) AND INTERLEUKIN 6 (IL-6) AND CAN DECREASE PROLIFERATION (>85%) IN A MIXED LYMPHOCYTE REACTION ASSAY WITH CONCANAVALIN A (CONA)-STIMULATED CANINE PMBCS)
LATOVETCEL [INN]

External Clinical & Regulatory Resources

NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus